Cargando…

Immune profiles and clinical outcomes between sepsis patients with or without active cancer requiring admission to intensive care units

BACKGROUND: Immunoparalysis was observed in both patients with cancer and sepsis. In cancer patients, Cytotoxic T lymphocyte antigen-4 and programmed cell death protein 1/programmed death-ligand 1 axis are two key components of immunoparalysis. Several emerging therapies against these two axes gaine...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Wen-Feng, Chen, Yu-Mu, Lin, Chiung-Yu, Huang, Kuo-Tung, Kao, Hsu-Ching, Fang, Ying-Tang, Huang, Chi-Han, Chang, Ya-Ting, Wang, Yi-His, Wang, Chin-Chou, Lin, Meng-Chih
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503229/
https://www.ncbi.nlm.nih.gov/pubmed/28692671
http://dx.doi.org/10.1371/journal.pone.0179749
_version_ 1783249058261893120
author Fang, Wen-Feng
Chen, Yu-Mu
Lin, Chiung-Yu
Huang, Kuo-Tung
Kao, Hsu-Ching
Fang, Ying-Tang
Huang, Chi-Han
Chang, Ya-Ting
Wang, Yi-His
Wang, Chin-Chou
Lin, Meng-Chih
author_facet Fang, Wen-Feng
Chen, Yu-Mu
Lin, Chiung-Yu
Huang, Kuo-Tung
Kao, Hsu-Ching
Fang, Ying-Tang
Huang, Chi-Han
Chang, Ya-Ting
Wang, Yi-His
Wang, Chin-Chou
Lin, Meng-Chih
author_sort Fang, Wen-Feng
collection PubMed
description BACKGROUND: Immunoparalysis was observed in both patients with cancer and sepsis. In cancer patients, Cytotoxic T lymphocyte antigen-4 and programmed cell death protein 1/programmed death-ligand 1 axis are two key components of immunoparalysis. Several emerging therapies against these two axes gained significant clinical benefit. In severe sepsis patients, immunoparalysis was known as compensatory anti-inflammatory response syndrome and this has been suggested as an important cause of death in patients with sepsis. It would be interesting to see if immune status was different in severe sepsis patients with or without active cancer. The aim of this study was to assess the differences in immune profiles, and clinical outcomes between severe sepsis patients with or without cancer admitted to ICU. METHODS: A combined retrospective and prospective observational study from a cohort of adult sepsis patients admitted to three medical ICUs at Kaohsiung Chang Gung Memorial Hospital in Taiwan between August 2013 and June 2016. RESULTS: Of the 2744 patients admitted to the ICU, 532 patients with sepsis were included. Patients were divided into those with or without active cancer according to their medical history. Of the 532 patients, 95 (17.9%) patients had active cancer, and 437 (82.1%) patients had no active cancer history. Patients with active cancer were younger (p = 0.001) and were less likely to have diabetes mellitus (p < 0.001), hypertension (p < 0.001), coronary artery disease (p = 0.004), chronic obstructive pulmonary disease (p = 0.002) or stroke (p = 0.002) compared to patients without active cancer. Patients with active cancer also exhibited higher baseline lactate levels (p = 0.038), and higher baseline plasma interleukin (IL)-10 levels (p = 0.040), higher trend of granulocyte colony-stimulating factor (G-CSF) (p = 0.004) compared to patients without active cancer. The 14-day, 28-day and 90-day mortality rates were higher for patients with active cancer than those without active cancer (P < 0.001 for all intervals). CONCLUSIONS: Among patients admitted to the ICU with sepsis, those with underling active cancer had higher baseline levels of plasma IL-10, higher trend of G-CSF and higher mortality rate than those without active cancer.
format Online
Article
Text
id pubmed-5503229
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-55032292017-07-25 Immune profiles and clinical outcomes between sepsis patients with or without active cancer requiring admission to intensive care units Fang, Wen-Feng Chen, Yu-Mu Lin, Chiung-Yu Huang, Kuo-Tung Kao, Hsu-Ching Fang, Ying-Tang Huang, Chi-Han Chang, Ya-Ting Wang, Yi-His Wang, Chin-Chou Lin, Meng-Chih PLoS One Research Article BACKGROUND: Immunoparalysis was observed in both patients with cancer and sepsis. In cancer patients, Cytotoxic T lymphocyte antigen-4 and programmed cell death protein 1/programmed death-ligand 1 axis are two key components of immunoparalysis. Several emerging therapies against these two axes gained significant clinical benefit. In severe sepsis patients, immunoparalysis was known as compensatory anti-inflammatory response syndrome and this has been suggested as an important cause of death in patients with sepsis. It would be interesting to see if immune status was different in severe sepsis patients with or without active cancer. The aim of this study was to assess the differences in immune profiles, and clinical outcomes between severe sepsis patients with or without cancer admitted to ICU. METHODS: A combined retrospective and prospective observational study from a cohort of adult sepsis patients admitted to three medical ICUs at Kaohsiung Chang Gung Memorial Hospital in Taiwan between August 2013 and June 2016. RESULTS: Of the 2744 patients admitted to the ICU, 532 patients with sepsis were included. Patients were divided into those with or without active cancer according to their medical history. Of the 532 patients, 95 (17.9%) patients had active cancer, and 437 (82.1%) patients had no active cancer history. Patients with active cancer were younger (p = 0.001) and were less likely to have diabetes mellitus (p < 0.001), hypertension (p < 0.001), coronary artery disease (p = 0.004), chronic obstructive pulmonary disease (p = 0.002) or stroke (p = 0.002) compared to patients without active cancer. Patients with active cancer also exhibited higher baseline lactate levels (p = 0.038), and higher baseline plasma interleukin (IL)-10 levels (p = 0.040), higher trend of granulocyte colony-stimulating factor (G-CSF) (p = 0.004) compared to patients without active cancer. The 14-day, 28-day and 90-day mortality rates were higher for patients with active cancer than those without active cancer (P < 0.001 for all intervals). CONCLUSIONS: Among patients admitted to the ICU with sepsis, those with underling active cancer had higher baseline levels of plasma IL-10, higher trend of G-CSF and higher mortality rate than those without active cancer. Public Library of Science 2017-07-10 /pmc/articles/PMC5503229/ /pubmed/28692671 http://dx.doi.org/10.1371/journal.pone.0179749 Text en © 2017 Fang et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Fang, Wen-Feng
Chen, Yu-Mu
Lin, Chiung-Yu
Huang, Kuo-Tung
Kao, Hsu-Ching
Fang, Ying-Tang
Huang, Chi-Han
Chang, Ya-Ting
Wang, Yi-His
Wang, Chin-Chou
Lin, Meng-Chih
Immune profiles and clinical outcomes between sepsis patients with or without active cancer requiring admission to intensive care units
title Immune profiles and clinical outcomes between sepsis patients with or without active cancer requiring admission to intensive care units
title_full Immune profiles and clinical outcomes between sepsis patients with or without active cancer requiring admission to intensive care units
title_fullStr Immune profiles and clinical outcomes between sepsis patients with or without active cancer requiring admission to intensive care units
title_full_unstemmed Immune profiles and clinical outcomes between sepsis patients with or without active cancer requiring admission to intensive care units
title_short Immune profiles and clinical outcomes between sepsis patients with or without active cancer requiring admission to intensive care units
title_sort immune profiles and clinical outcomes between sepsis patients with or without active cancer requiring admission to intensive care units
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503229/
https://www.ncbi.nlm.nih.gov/pubmed/28692671
http://dx.doi.org/10.1371/journal.pone.0179749
work_keys_str_mv AT fangwenfeng immuneprofilesandclinicaloutcomesbetweensepsispatientswithorwithoutactivecancerrequiringadmissiontointensivecareunits
AT chenyumu immuneprofilesandclinicaloutcomesbetweensepsispatientswithorwithoutactivecancerrequiringadmissiontointensivecareunits
AT linchiungyu immuneprofilesandclinicaloutcomesbetweensepsispatientswithorwithoutactivecancerrequiringadmissiontointensivecareunits
AT huangkuotung immuneprofilesandclinicaloutcomesbetweensepsispatientswithorwithoutactivecancerrequiringadmissiontointensivecareunits
AT kaohsuching immuneprofilesandclinicaloutcomesbetweensepsispatientswithorwithoutactivecancerrequiringadmissiontointensivecareunits
AT fangyingtang immuneprofilesandclinicaloutcomesbetweensepsispatientswithorwithoutactivecancerrequiringadmissiontointensivecareunits
AT huangchihan immuneprofilesandclinicaloutcomesbetweensepsispatientswithorwithoutactivecancerrequiringadmissiontointensivecareunits
AT changyating immuneprofilesandclinicaloutcomesbetweensepsispatientswithorwithoutactivecancerrequiringadmissiontointensivecareunits
AT wangyihis immuneprofilesandclinicaloutcomesbetweensepsispatientswithorwithoutactivecancerrequiringadmissiontointensivecareunits
AT wangchinchou immuneprofilesandclinicaloutcomesbetweensepsispatientswithorwithoutactivecancerrequiringadmissiontointensivecareunits
AT linmengchih immuneprofilesandclinicaloutcomesbetweensepsispatientswithorwithoutactivecancerrequiringadmissiontointensivecareunits